Login Register Cart 0
Generic placeholder image

Letters in Organic Chemistry

Editor-in-Chief

ISSN (Print): 1570-1786
ISSN (Online): 1875-6255

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

Synthesis, Evaluation of Biological Activity, Docking and Molecular Dynamic Studies of Pyrimidine Derivatives

Author(s): Shahin Boumi, Jafar Moghimirad, Massoud Amanlou, Seyed Nasser Ostad, Shohreh Tavajohi and Mohsen Amini*

Volume 18, Issue 3, 2021

Published on: 05 July, 2020

Page: [212 - 225] Pages: 14

DOI: 10.2174/1570178617999200706005824

Price: $65

Abstract

The microtubule is composed of αβ-tubulin heterodimers and is an attractive target for the design of anticancer drugs. Over the years, various compounds have been developed and their effect on tubulin polymerization has been studied. Despite great efforts to make an effective drug, no drug has been introduced which inhibit colchicine binding site. In the current work, a series of pyrimidine derivatives were designed and synthesized. Furthermore, their cytotoxic activities were evaluated and molecular docking studies were performed. Twenty compounds of pyrimidine were synthesized in 2 different groups. In the first group, 4,6-diaryl pyrimidine was connected to the third aryl group via thiomethylene spacer. In the second group, this linker was substituted by S-CH2-triazole moiety. The cytotoxic activity of these compounds was evaluated against 4 different cell lines (HT-29, MCF-7, T47D, NIH3T3). Compounds 6d, 6m, 6p showed potent cytotoxic activity against MCF7 cancerous cell lines. Between these compounds, compound 6p did not show cytotoxic activity against NIH- 3T3 (normal cell) cell line. Docking studies show that these compounds occupy colchicine binding site in tubulin protein and probably their anticancer mechanism is inhibition of tubulin polymerization. Altogether, with respect to obtained results, it is attractive and beneficial to further investigation on pyrimidine scaffold as antimitotic agents. Attention to the selectivity index of 6p on MCF7 cell line could be valuable in design new chemical agents for the treatment of breast cancer.

Keywords: Synthesis, pyrimidine, docking, cytotoxic, anticancer, MTT assay.

« Previous Next »
Graphical Abstract

[1]
Regina, G.L.; Bai, R.; Coluccia, A.; Famiglini, V.; Pelliccia, S.; Passacantilli, S.; Mazzoccoli, C.; Ruggieri, V.; Sisinni, L.; Bolognesi, A.; Rensen, W.M.; Miele, A.; Nalli, M.; Alfonsi, R.; Marcotullio, L.D.; Gulino, A.; Brancale, A.; Novellino, E.; Dondio, G.; Vultaggio, S.; Varasi, M.; Mercurio, C.; Hamel, E.; Lavia, P.R. J. Med. Chem., 2014, 57, 6531-6552.
[2]
Ghasemi, M.; Ghadbeighi, S.; Amirhamzeh, A.; Tabatabai, S.A. Ostad S. N. Shafiee A. Amini M. Lett. Drug Des. Discov., 2016, 13, 121-128.
[http://dx.doi.org/10.2174/1570180812666150722235902]
[3]
Assadieskandar, A.; Amini, M.; Ostad, S.N.; Riazi, G.H.; Cheraghi-Shavi, T.; Shafiei, B.; Shafiee, A. Bioorg. Med. Chem., 2013, 21(10), 2703-2709.
[http://dx.doi.org/10.1016/j.bmc.2013.03.011] [PMID: 23566762]
[4]
Saeedian, E.M.; Amini, M. Molbank, 2018, 2018, M1002.
[http://dx.doi.org/10.3390/M1002]
[5]
Lu, Y.; Chen, J.; Wang, J.; Li, C.M.; Ahn, S.; Barrett, C.M.; Dalton, J.T.; Li, W.; Miller, D.D. J. Med. Chem., 2014, 57(17), 7355-7366.
[http://dx.doi.org/10.1021/jm500764v] [PMID: 25122533]
[6]
Vosooghi, M.; Amini, M. Expert Opin. Drug Discov., 2014, 9(3), 255-267.
[http://dx.doi.org/10.1517/17460441.2014.883377] [PMID: 24483845]
[7]
Rizzo, M.T. Clin. Chim. Acta, 2011, 412(9-10), 671-687.
[http://dx.doi.org/10.1016/j.cca.2010.12.026] [PMID: 21187081]
[8]
Subhashini, J.; Mahipal, S.V.; Reddanna, P. Cancer Lett., 2005, 224(1), 31-43.
[http://dx.doi.org/10.1016/j.canlet.2004.11.002] [PMID: 15911099]
[9]
Zhang, G.S.; Liu, D.S.; Dai, C.W.; Li, R. J. Am. J. Hematol., 2006, 81, 242-255.
[http://dx.doi.org/10.1002/ajh.20542]
[10]
Konturek, P.C.; Kania, J.; Burnat, G.; Hahn, E.G.; Konturek, S.J.J. Phisiol. Pharmacol., 2005, 56, 57-73.
[11]
Kumar, B.; Sharma, P.; Gupta, V.P.; Khullar, M.; Singh, S.; Dogra, N.; Kumar, V. Bioorg. Chem., 2018, 78, 130-140.
[http://dx.doi.org/10.1016/j.bioorg.2018.02.027] [PMID: 29554587]
[12]
Saravani, F.; Saeedian Moghadam, E.; Salehabadi, H.; Ostad, S.N.; Hamedani, M.P.; Amanlou, M.; Faramarzi, M.A. Lett. Drug Des. Discov., 2019, 16, 1194-1201.
[http://dx.doi.org/10.2174/1570180815666180727114216]
[13]
Saeedian, S.M. Hamel, E.; Shahsavari, Z.; Amini, M. PS (Wash., D.C.), 2019, 27, 179-189.
[14]
Zareian, B.; Ghadbeighi, S.; Amirhamzeh, A.; Ostad, S.N.; Shafiee, A.; Amini, M. Med. Chem., 2016, 12(4), 394-401.
[http://dx.doi.org/10.2174/1573406412666151112125149 ] [PMID: 26558375]
[15]
Salehi, M.; Ostad, S.N.; Riazi, G.H.; Assadieskandar, A.; Shavi, T.C.; Shafiee, A.; Amini, M. Med. Chem. Res., 2014, 23, 1465-1473.
[http://dx.doi.org/10.1007/s00044-013-0754-6]
[16]
Ghadbegi, S.; Ostad, S.N.; Shafiee, A.; Amini, M. Lett. Drug Des. Discov., 2015, 12, 754-759.
[http://dx.doi.org/10.2174/1570180812666150326004723]
[17]
Miralinaghi, P.; Salimi, M.; Amirhamzeh, A.A.; Norouzi, M.; Kandelousi, H.M.; Shafiee, A.; Amini, M. Med. Chem. Res., 2013, 22, 4253-4262.
[http://dx.doi.org/10.1007/s00044-012-0436-9]
[18]
Moghadam, E.S.; Saravani, F.; Ostad, S.N.; Tavajohi, S.; Hamedani, M.P.; Amini, M. Heterocycl. Commun., 2018, 24, 211-217.
[http://dx.doi.org/10.1515/hc-2018-0016]

Rights & Permissions Print Cite
Article Metrics
29
1
© 2024 Bentham Science Publishers | Privacy Policy